We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cross-Contamination and Caregiver Safety Drive Retractable Safety Syringes Market

By HospiMedica staff writers
Posted on 24 Jul 2007
Sharps cross-contamination and caregiver safety concerns continue driving technology and commercial innovation in the safety syringe sector, according to a new report. More...


The report, published by Greystone Associates (Amherst, NH, USA), a medical and healthcare technologies consulting firm, stated that the market for safety syringes is being driven by worker safety concerns and the regulatory activity resulting from these concerns, such as the Needlestick Safety and Prevention Act in the United States, a U.S. government regulation regarding syringe needle handling and disposal. This trend is occurring at a much slower rate in Europe, where the time lag of safety legislation has syringe usage still being primarily influenced for the most part by healthcare economics.

In an average hospital, workers incur approximately 30 needle stick or other sharps injuries per 100 beds per year; research shows that as many as 60% of incidents remain unreported. Laboratory and other technical support staff are also exposed to risk. The U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) has recommended that needles not be recapped and, if they must be recapped, that a method other than the traditional two-handed technique be used. The alternatives to recapping include the use of safety syringes or the disposal of uncapped needles into permanent sealable containers (e.g., sharps containers).

Greystone Associates estimate that the retractable safety syringes market is set to reach US$350 million over the next four years, representing an annual growth rate of 13%.


Related Links:
U.S. Centers for Disease Control and Prevention
Greystone Associates

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.